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Supplemental Experimental Procedures
Constructs
For PCR mutagenesis, corresponding sequences are listed in Table S1 . CMV-VSVG, psPAX2, pLKO1puro and pSIV3+ were described elsewhere (Manel et al., 2010) . Replication-competent X4-GFP is NL4-3 with GFP in Nef (Motsinger et al., 2002; Unutmaz et al., 1999) . pTRIP-CMV-puro-2A and pTRIP-SFFV (coding for GFP) were generated from pTRIP (Zennou et al., 2000) and GAE-SFFV-GFP-WPRE obtained from Jean-Luc Battini (Mamede et al., 2013) . pCIG3 N (a generous gift from Towers Greg (Bock et al., 2000) ), pCL10A1 (Naviaux et al., 1996) and pRV.GFP were previously described. shRNA against LacZ, MX2, TNPO3, CPSF6, CypA(PPIA), RANBP2, NUP153, TRIM5 and SUN2 were in the pLKO1puro vector and are listed in Table S2 .
Cells
Human peripheral blood mononuclear cells were isolated from buffy coats from normal human donors (approved by the Institut National de la Santé et de la Recherche Médicale ethics committee) using Ficoll-Paque PLUS (GE). Macaque peripheral blood mononuclear cells were isolated from macaques using 5% PBS 95% FicollPaque PLUS. CD14+ cells were isolated by a positive selection with anti-human CD14 magnetic beads (Miltenyi). Purity was checked by flow cytometry using an anti-CD14 antibody (antibodies are listed in Table  S3 ) and purity was superior to 99%. CD14+ cells were cultured in RPMI medium, 10% FBS (Biowest), Penicillin-Streptomicin, Gentamicin (50 µg/ml, Gibco) and HEPES (Gibco) in the presence of recombinant human GM-CSF (Miltenyi) at 10ng/ml and IL-4 (Miltenyi) at 50ng/ml. Fresh media was added at day 3, and cells were stimulated or infected at day 4. CD4+ T cells were isolated by a positive selection with anti-human CD4 magnetic beads (Miltenyi) from the CD14-negative fraction of PBMCs. Purity was checked by flow cytometry using an anti-CD4 antibody (antibodies are listed in Table S3 ) and purity was superior to 95-96%. CD4+ cells were cultured at 1 million per ml (200µl/well in round-bottomed 96-well plates) in RPMI medium, 10% FBS (Biowest), Penicillin-Streptomicin, Gentamicin (50µg/ml, Gibco) and 1000 U/ml human IL-2 and activated with the T Cell Activation/Expansion Kit (Miltenyi). Bone marrow was taken from Sun2 -/-, Sun1 -/-or WT littermate control mice, to differentiate mouse dendritic cells (BMDCs). Mouse bone-marrow progenitors were cultured for 10 days in DC medium (IMDM, FCS (10%), Glutamine (20mM), pen-strep (100U/mL) and 2-mercaptoethanol (50µM)), supplemented with granulocytemacrophage colony stimulating factor (50ng/mL)-containing supernatant obtained from transfected J558 cells. After 4 days of differentiation, all cells were passed to a density of 10 millions per 165 cm 2 .
Mice
All animal care and experimental procedures were conducted in accord with requirements approved by the Institutional Animal Care and Use Committee of Yale University. Sun1 -/-(strain B6;129S6-Sun1 tm1Mha n/J), Sun2 -/-(strain B6;129S6-Sun2 tm1Mhan /J) and C57BL/6 WT mice were obtained from Jackson Labs. Sun1 -/-mice were previously generated through the replacement of exons 10-13 with a neomycin resistance cassette (Ding et al., 2007) . Sun2 -/-mice were previously generated through the replacement of exons 11-16 and part of exon 17 with a neomycin resistance cassette (Lei et al., 2009) .
Virus production
For transfection of 3µg plasmid DNA per well, plasmid quantities were as follows: for VSV-G pseudotyped SIVmac VLPs, 0.4µg CMV-VSVG and 2.6µg pSIV3 + ; for HIV-1, HIV-2 and SIVmac239 VSV-G pseudotyped viruses, 0.4µg CMV-VSVG and 2.6µg HIV or SIV DNA; for replication-competent HIV-1, 3µg X4-GFP; for MLV VSV-G pseudotyped viruses, 0.4µg CMV-VSVG, 1.6µg MLV DNA (pRV.GFP) and 1µg pCL10A1 (TRIM5α resistant) or pCIG3 N (TRIM5α sensitive); for shRNA vectors in MDDCs and THP-1 cells, 0.4µg CMV-VSV-G, 1µg psPAX2 and 1.6µg pLKO1puro-derived shRNA; for shRNA vectors in primary CD4+ T cells, 0.2µg HXB2 envelope expression plasmid (Boggiano et al., 2007) , 0.2µg CMV-VSV-G, 1µg psPAX2 and 1.6 µg pLKO1puro-derived shRNA; for expression vectors 0.4 µg CMV-VSV-G, 1µg psPAX2 and 1.6µg pTRIP-CMV-tagRFP-2A, pLX304 (Empty vector) or pLX304-SUN2 (overexpression SUN2-V5, clone HsCD00436663 from DNASU; Genbank: AM392760). Empty pLX304 was generated by removing SUN2 from pLX304-SUN2 with BsrGI.
Infections.
For MDDCs infection, 50 µl of media or SIVmac VLPs were first added and 100 µl of media or dilutions of viral supernatants to 100µl of cells. Azidothymidine (AZT, SIGMA), Raltegravir (RAL, Euromedex) or Cyclosporin A (CypA, Selleckchem) were added respectively at 24µM, 20µM and 2µM. CBS1 is a small molecular inhibitor of CypA that binds the hydrophobic and the Abu pockets of CypA (Guichou et al., 2011) (Hakim Ahmed-Belkacem, Jean-François Guichou, Jean-Michel Pawlotsky, unpublished data) and was added at 2µM. For CD4+ T cells infection, one hundred microliter of media or dilutions of viral supernatants were added to 100µl of cells in presence or not of 2 µM of CsA, 60 µM of CBS1 or 25 µM of AZT plus 10 µM of Nevirapine (NVP) (Sigma). For BMDCs infection, 100 µl of media or dilutions of viral supernatants were added in presence or not of 2 µM of CsA. 72h after infection, cells were stained with anti-mouse CD11c and analyzed. Table S2 lists the shRNA sequences used. THP-1 cells were transduced with a control empty vector pLKO1puro (shRNA vector targeting LacZ) or a single shRNA vectors in pLKO1puro. Puromycin was added at day 2 (2ng/ml). Knock-down efficiency was measured by western blotting or qPCR at day 10 (for THP-1 cells). Cells were seeded at 1 million per ml in 96-well flat bottom plate in 200 µl of final volume treated or not with PMA (30ng/ml) for 16 hours. Media was replaced with 100µl of fresh media and 100µl of media or dilutions of viral supernatants were added. Monocytes were transduced with shRNA vectors as previously described (Manel et al., 2010; Satoh and Manel, 2013) . Knock-down efficiency was measured by western blotting or qPCR at day 4 or 6. DCs were harvested, counted, seeded at 0.5 million per ml in 96-well U bottom plate and infected or stimulated in 200 µl of final volume. For knock-down experiments in CD4+ T cells, after 24h of activation in 96-well plates, media was changed by 100µl of fresh media with 8µg/ml of protamine and cells were transduced with 100µl of shRNA lentivector supernatants. Cells were spinoculated at 1200g, 2h at 25°C. At day 3, media was changed in presence of puromycin (2ng/ml). For single-round infection experiments, cells were split at day 4 and day 6. At day 7, CD4+ T cells were harvested, counted, seeded and infected. For experiment with replicationcompetent virus X4-GFP, cells were harvested, counted, seeded and infected at day 4. 10h later, viral inoculum was washed. Accumulation of HIV-1 p24 was measured at days 5 to 8 by ELISA (Clontech Takara Lenti-X p24 Rapid Titer Kit). For overexpression in DCs, monocytes were transduced with vectors pTRIP-CMV-tagRFP-2A or pTRIP-CMV-tagRFP-2A-FLAG-ntCypA as previously described (Manel et al., 2010; Satoh and Manel, 2013) . Overexpression efficiency was measured by western blotting or RFP expression at day 6. For overexpression in HeLa, cells were transduced with pLX304 or pLX304-SUN2 and selected with 15µg/mL of blasticidine. Overexpression efficiency was measured by western blotting at day 10.
Knock-down and overexpression
HIV cDNA Real-time PCR Total cellular DNA was harvested using a Nucleospin Tissue kit (Machery-Nagel). Real-time PCR analysis was adapted from (Brussel and Sonigo, 2003) and performed in a Roche LightCycler 480 using Roche 480 SYBR Green I master reagent in 20 µl final volume per well according to manufacturer specifications. Each sample was measured in triplicate for all primers (primer sequences are listed in Table S5 ). For beta-globin, primers were bglobin-f and bglobin-r. For HIV-2 late RT, primers were hiv2-3'U3-fwd and hiv2-psi-rev. For HIV-2 2LTR, primers were hiv2-3'U3-rev and hiv2-R-fwd. For HIV-2 integrated DNA two rounds of amplification were performed. For the first round, primers were alu1 and hiv2-r. For the second round, 1 µl of first-round reaction was used as template, and primers were hiv2-f2 and hiv2-r2. For HIV-1 late RT, primers were hiv1-3'U3-fwd and hiv1-psi-rev2. For HIV-1 2LTR JNCT, primers were Junct4 -fwd and Junct2-rev. For HIV-1 integrated DNA two rounds of amplification were performed. For the first round, primers were alu1 and hiv1-psi-rev2. For the second round, 1 µl of first-round reaction was used as template, and primers were hiv1-f2 and hiv1-r2. Cycling conditions were 1x 95°C 5'; 35x 95°C, 10"-50°C or 65°C, 20"-72°C 30". Relative concentrations of late RT, 2LTR and integrated viral DNA were calculated relative to beta-globin using the ∆Ct method.
Gene expression quantification
Ten days after lentiviral vector transduction, total RNA was extracted from 1 million THP-1 cells using Nucleospin RNA II kit (Macherey-Nagel). cDNA was synthesized with random hexamer from 0.1µg total RNA using SuperScript III Reverse Transcriptase (Invitrogen). Real-time qPCR was performed using SYBR Green I Master (Roche). The relative quantities of target mRNAs were calculated between target RNA Cp and ACTB Cp (2 -∆Cp method). The primer sequences are listed in Table S4 .
Western Blotting 0.2 to 2 millions cells were lysed in 80 µL of Lysis buffer (50mM Tris HCl pH 8, 120mM NaCl, 4mM EDTA, 1% NP40 and 1x EDTA-free protease inhibitors cocktail (Roche)). Lysates were cleared by centrifugation at 6000g for 7 minutes at 4°C. Virus supernatants were filtered at 0.45µm, centrifugated at 16000g for 1 h 30 min at 4°C. Virus pellets were lysed in 15µl of Lysis buffer. Cellular and viral protein lysates were resolved on 4%-20% Biorad precast SDS-PAGE gels and transferred on nitrocellulose membrane. Proteins were blotted with antibodies as follow: mouse anti-Gag/capsid; mouse anti-Vpx; mouse anti-actin; rabbit anti-CypA (antibodies are listed in Table S3 ). ECL signal was recorded on the ChemiDoc XRS Biorad Imager. Data was analyzed and quantified with the Image Lab software (Biorad).
Morphological Analysis
Cells were subjected to cytospin and colored with May-Grunwald/Giemsa staining. Pictures were taken with a Nikon DS-FI1 High-definition color camera head on a Nikon Eclipse TS100 inverted microscope.
Immunofluorescence
HeLa cells monolayers grown on glass poly-Lysine coverslip were fixed with 4% paraformaldehyde in PBS at room temperature for 10 min and incubated in Glycine-PBS buffer (375 mg Glycine in 50ml of PBS) for 15min. Cells were permeabilized in 0.2% BSA, 0.1% Saponin in PBS for 30min and stained with SUN2 (Atlas Ig -1/1000) and V5 (eBioscience Ig -1/1000) in 0.2% BSA, 0.1% Saponin in PBS at room temperature for 5h. Followed this incubation, washes and secondary antibody staining were performed in the same buffers, with the corresponding immunoglobulin G (IgG) antibody conjugated to Alexa 488 (SUN2) or Alexa 647 (V5 tag) at the dilution of 1/500 at room temperature for 1h. The cells were mounted onto glass slides by using Dapi Fluoromont G (eBioscience) to stain nuclei and imaged on a Zeiss LSM 780 Confocal Microscope. ImageJ (National Institutes of Health, Bethesda MD) software was used for image processing and for the Z-projection (base on the maximum of intensity for each z stack).
Ethic approval for macaque blood
Adult cynomolgus macaques (Macaca fascicularis) were used at CEA in accordance with French national regulation and under national veterinary inspectors (CEA permit no. A 92-032-02). CEA is in compliance with Standards for Human Care and Use of Laboratory of the Office for Laboratory Animal Welfare (OLAW; OLAW assurance no. A5826-01). The use of nonhuman primates at CEA is in accordance with recommendation with the European Directive (2010/63; recommendation no. 9). No suffering was specifically associated with the treatment and sample procedure to obtain nasal washes. The animals were used under the supervision of the veterinarians in charge of the animal facility. No suffering was specifically associated with the sampling procedure to obtain peripheral blood. Peripheral blood was obtained from healthy animals by venipuncture at the femoral vein after sedation with ketamine chrorhydrate (Rhone-Merieux, Lyon, France, 10 mg/kg) as previously described (Dioszeghy et al., 2006) and collected on heparinized CPT tubes (BD, Franklin Lakes, NJ).
